Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer / 癌症
Chinese Journal of Cancer
;
(12): 41-49, 2015.
Artigo
em Inglês
| WPRIM
| ID: wpr-349613
ABSTRACT
Epithelial ovarian cancer (OC) is a common gynecologic malignancy in women. The standard treatment for OC is maximal cytoreductive surgical debulking followed by platinum-based chemotherapy. Despite the high response rate to primary therapy, approximately 85% of patients will develop recurrent ovarian cancer (ROC). This review identifies the clinical use of trabectedin in the treatment algorithm for ROC, with specific emphasis on platinum-sensitive ROC, for which trabectedin in combination with pegylated liposomal doxorubicin has been approved as a treatment protocol. The main mechanisms of action of trabectedin at the cellular level and in the tumor microenvironment is also discussed as bases for identifying biomarkers for selecting patients who may largely benefit from trabectedin-based therapies.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Ovarianas
/
Farmacologia
/
Polietilenoglicóis
/
Dano ao DNA
/
Doxorrubicina
/
Ensaios Clínicos como Assunto
/
Neoplasias Epiteliais e Glandulares
/
Antineoplásicos Alquilantes
/
Tetra-Hidroisoquinolinas
/
Usos Terapêuticos
Tipo de estudo:
Estudo diagnóstico
/
Guia de Prática Clínica
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Chinese Journal of Cancer
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS